Analysis of HER2/GRB7 co-expression and its association with clinicopathological variables in a group of Colombian women diagnosed with invasive breast cancer

Ban KA, Godellas CV. Epidemiology of breast cancer. Surg Oncol Clin N Am. 2014;23(3):409–22. http://dx.doi.org/10.1016/j.soc.2014.03.011

Di Sibio A, Abriata G, Forman D, Sierra MS. Female breast cancer in Central and South America. Cancer Epidemiol. 2016;44:S110–20. http://dx.doi.org/10.1016/j.canep.2016.08.010

Lei S, Zheng R, Zhang S, Chen R, Wang S, Sun K, et al. Breast cancer incidence and mortality in women in China: temporal trends and projections to 2030. Cancer Biol Med. 2021;18(3):900–9. https://doi.org/10.20892/j.issn.2095-3941.2020.0523

Barbieri RL. Chapter 10 - Breast. Strauss JF, Barbieri RL, Yen and Jaffe’s Reproductive Endocrinology (Eighth Edition). Elsevier. 2019;248-255.e3. https://doi.org/10.1016/B978-0-323-47912-7.00010-X

Pardo C, de Vries E, Buitrago L, Gamboa Ó. Atlas de mortalidad por cáncer en Colombia. Cuarta edición. Bogotá D. C. Instituto Nacional de Cancerología, 2017, v.1. p. 124.Disponible en: https://www.cancer.gov.co/recursos_user/files/libros/archivos/ATLAS_de_Mortalidad_por_cancer_en_Colombia.pdf

Turashvili G, Brogi E. Tumor heterogeneity in breast cancer. Front Med. 2017;4:1-11. https://doi.org/10.3389/fmed.2017.00227

Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747–52. https://doi.org/10.1038/35021093

Howlader N, Cronin KA, Kurian AW, Andridge R. Differences in breast cancer survival by molecular subtypes in the United States. Cancer Epidemiol Biomarkers Prev. 2018;27(6):619–26. https://doi.org/10.1158/1055-9965.EPI-17-0627

Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. PNAS. 2001;98(19): 10869 –74. https://doi.org/10.1073/pnas.191367098

Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ. Strategies for subtypes-dealing with the diversity of breast cancer: Highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2011. Ann Oncol. 2011;22(8):1736–47. https://doi.org/10.1093/annonc/mdr304

DeSantis CE, Fedewa SA, Goding Sauer A, Kramer JL, Smith RA, Jemal A. Breast cancer statistics, 2015: Convergence of incidence rates between black and white women. CA Cancer J Clin. 2016;66(1):31–42. https://doi.org/10.3322/caac.21320

Troester MA, Sun X, Allott EH, Geradts J, Cohen SM, Tse CK, et al. Racial differences in PAM50 subtypes in the Carolina Breast Cancer Study. J Natl Cancer Inst. 2018;110(2):1–7. https://doi.org/10.1093/jnci/djx135

Hines LM, Risendal B, Byers T, Mengshol S, Lowery J, Singh M. Ethnic disparities in breast tumor phenotypic subtypes in hispanic and non-hispanic white women. J Women’s Heal. 2011;20(10):1543–50. https://doi.org/10.1089/jwh.2010.2558

Gómez R, Ossa CA, Montoya ME, Echeverri C, Ángel G, Ascuntar J, et al. Impact of immunohistochemistry-based molecular subtype on chemosensitivity and survival in Hispanic breast cancer patients following neoadjuvant chemotherapy. Ecancermedicalscience. 2015;9:562. https://doi.org/10.3332/ecancer.2015.562

Serrano-Gomez SJ, Sanabria-Salas MC, Hernández-Suarez G, García O, Silva C, Romero A, et al. High prevalence of luminal B breast cancer intrinsic subtype in Colombian women. Carcinogenesis. 2016;37(7):669–76. https://doi.org/10.1093/carcin/bgw043

Pinto JA, Saravia CH, Flores C, Araujo JM, Martínez D, Schwarz LJ, et al. Precision medicine for locally advanced breast cancer: Frontiers and challenges in Latin America. Ecancermedicalscience. 2019;13:896. https://doi.org/10.3332/ecancer.2019.896

Pérez-Rodríguez G, Aranda-Moreno C, Olivares-Corichi IM, Garcia-Sanchez JR. The association of subtypes of breast cancer with tumour characteristics and reproductive factors in 1326 Mexican women. Contemp Oncol (Pozn). 2015;19(6):462–6. https://doi.org/10.5114/wo.2015.56652

Serrano-Gómez SJ, Sanabria-Salas MC, Garay J, Baddoo MC, Hernández-Suarez G, Mejía JC, et al. Ancestry as a potential modifier of gene expression in breast tumors from Colombian women. PLoS One. 2017;12(8):e0183179. https://doi.org/10.1371/journal.pone.0183179

Nencioni A, Cea M, Garuti A, Passalacqua M, Raffaghello L, Soncini D, et al. Grb7 upregulation is a molecular adaptation to HER2 signaling inhibition due to removal of Akt-mediated gene repression. PLoS One. 2010;5(2):1–10. https://doi.org/10.1371/journal.pone.0009024

Pradip D, Bouzyk M, Dey N, Leyland-Jones B. Dissecting GRB7-mediated signals for proliferation and migration in HER2 overexpressing breast tumor cells: GTP-ase rules. Am J Cancer Res. 2013;3(2):173–95. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23593540%0Ahttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC3623837

Bivin WW, Yergiyev O, Bunker ML, Silverman JF, Krishnamurti U. GRB7 expression and correlation with HER2 amplification in invasive breast carcinoma. Appl Immunohistochem Mol Morphol. 2017;25(8):553–8. https://doi.org/10.1097/PAI.0000000000000349

Nadler Y, González AM, Camp RL, Rimm DL, Kluger HM, Kluger Y. Growth factor receptor-bound protein-7 (Grb7) as a prognostic marker and therapeutic target in breast cancer. Ann Oncol. 2009;21(3):466–73. https://doi.org/10.1093/annonc/mdp346

McCann KE, Slamon DJ. Chapter 1 - The molecular biology of HER2 and HER2-Targeted therapies. In: Hurvitz S, McCann K. HER2-Positive breast cancer. Elsevier. 2019. p. 1–11. http://dx.doi.org/10.1016/B978-0-323-58122-6.00001-5

Luoh SW, Wagoner W, Wang X, Hu Z, Lai X, Chin K, et al. GRB7 dependent proliferation of basal-like, HER-2 positive human breast cancer cell lines is mediated in part by HER-1 signaling. Mol Carcinog. 2019;58(5):699–707. https://doi.org/10.1002/mc.22963

Wolff AC, Elizabeth Hale Hammond M, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/ College of American Pathologists Clinical Practice Guideline focused update. J Clin Oncol. 2018;36(20):2105–22. https://doi.org/10.1200/JCO.2018.77.8738

Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B, et al. Personalizing the treatment of women with early breast cancer: Highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 2013;24(9):2206–23. https://doi.org/10.1093/annonc/mdt303

Vallejos CS, Gómez HL, Cruz WR, Pinto JA, Dyer RR, Velarde R, et al. Breast cancer classification according to immunohistochemistry markers: Subtypes and association with clinicopathologic variables in a Peruvian hospital database. Clin Breast Cancer. 2010;10(4):294–300. http://dx.doi.org/10.3816/CBC.2010.n.038

Ramsey B, Bai T, Hanlon Newell A, Troxell M, Park B, Olson S, et al. GRB7 protein over-expression and clinical outcome in breast cancer. Breast Cancer Res Treat. 2011;127(3):659–69. https://doi.org/10.1007/s10549-010-1010-0

Simon SD, Bines J, Werutsky G, Nunes JS, Pacheco FC, Segalla JG, et al. Characteristics and prognosis of stage I-III breast cancer subtypes in Brazil: The AMAZONA retrospective cohort study. Breast. 2019;44:113–9. https://doi.org/10.1016/j.breast.2019.01.008

Kim J, Lee Y, Yoo T, Kim J, Hyun J, Park I, et al. Organ-specific recurrence or metastatic pattern of breast cancer according to biological subtypes and clinical characteristics. J Breast Dis. 2019;7(1):30–7. https://doi.org/10.14449/jbd.2019.7.1.30

Prat A, Pineda E, Adamo B, Galván P, Fernández A, Gaba L, et al. Clinical implications of the intrinsic molecular subtypes of breast cancer. Breast. 2015;24(Suppl 2):S26–35. https://doi.org/10.1016/j.breast.2015.07.008

Blows FM, Driver KE, Schmidt MK, Broeks A, van Leeuwen FE, Wesseling J, et al. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: A collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med. 2010;7(5):e1000279. https://doi.org/10.1371/journal.pmed.1000279

Cheang MCU, Chia SK, Voduc D, Gao D, Leung S, Snider J, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 2009;101(10):736–50. https://doi.org/10.1093/jnci/djp082

Choi N, Lee SW, Lim Y, Kang E, Kim EK, Kim YJ, et al. Failure patterns between HER2-Negative and HER2-Positive luminal B breast cancer. Ann Breast Cancer. 2019;2(1):1–6. Available from: https://meddocsonline.org/annals-of-breast-cancer/failure-patterns-between-her2-negative-and-her2-positive-luminal-B-breast-cancer.pdf

Ding NH, Liu CF, Hu C, Yuan JQ, Liao WH, Xiao Z. Prognostic factors for luminal B-like breast cancer. Curr Med Sci. 2019;39(3):396–402. https://doi.org/10.1007/s11596-019-2049-8

Hashmi AA, Aijaz S, Khan SM, Mahboob R, Irfan M, Zafar NI, et al. Prognostic parameters of luminal A and luminal B intrinsic breast cancer subtypes of Pakistani patients. World J Surg Oncol. 2018;16(1):1–6. https://doi.org/10.1186/s12957-017-1299-9

Park S, Koo JS, Kim MS, Park HS, Lee JS, Lee JS, et al. Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry. Breast. 2012;21(1):50–7. http://dx.doi.org/10.1016/j.breast.2011.07.008

Li J, Chen Z, Su K, Zeng J. Clinicopathological classification and traditional prognostic indicators of breast cancer. Int J Clin Exp Pathol. 2015;8(7):8500–5. PMID: 26339424

Gonzalez-Angulo AM, Litton JK, Broglio KR, Meric-Bernstam F, Rakkhit R, Cardoso F, et al. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol . 2009;27(34):5700–6. https://doi.org/10.1200/JCO.2009.23.2025

Giricz O, Calvo V, Pero SC, Krag DN, Sparano JA, Kenny PA. GRB7 is required for triple-negative breast cancer cell invasion and survival. Breast Cancer Res Treat. 2012;133(2):607–15. https://doi.org/10.1007/s10549-011-1822-6

Lim RCC, Price JT, Wilce JA. Context-dependent role of Grb7 in HER2+ve and triple-negative breast cancer cell lines. Breast Cancer Res Treat. 2014;143(3):593–603. https://doi.org/10.1007/s10549-014-2838-5

Sparano JA, Goldstein LJ, Childs BH, Shak S, Brassard D, Badve S, et al. Relationship between quantitative GRB7 RNA expression and recurrence after adjuvant anthracycline chemotherapy in triple-negative breast cancer. Clin Cancer Res. 2011;17(22):7194–203. https://doi.org/10.1158/1078-0432.CCR-10-3357

Bai T, Luoh SW. GRB-7 facilitates HER-2/Neu-mediated signal transduction and tumor formation. Carcinogenesis. 2008;29(3):473–9. https://doi.org/10.1093/carcin/bgm221

Howlader N, Altekruse SF, Li CI, Chen VW, Clarke CA, Ries LAG, et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst. 2014;106(5): dju055. https://doi.org/10.1093/jnci/dju055

Zhao HB, Zhang XF, Jia XL, Wang H Bin. Grb7 is over-expressed in cervical cancer and facilitate invasion and inhibit apoptosis in cervical cancer cells. Pathol Res Pract. 2017;213(9):1180–4. http://dx.doi.org/10.1016/j.prp.2017.05.013

Petit T, Wilt M, Velten M, Millon R, Rodier JF, Borel C, et al. Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. Eur J Cancer. 2004;40(2):205–11. https://doi.org/10.1016/S0959-8049(03)00675-0

Tao M, Chen S, Zhang X, Zhou Q. Ki-67 labeling index is a predictive marker for a pathological complete response to neoadjuvant chemotherapy in breast cancer: A meta-analysis. Medicine (Baltimore). 2017;96(51):e9384. https://doi.org/10.1097/MD.0000000000009384

Li X, Krishnamurti U, Bhattarai S, Klimov S, Reid MD, O’Regan R, et al. Biomarkers Predicting pathologic complete response to neoadjuvant chemotherapy in breast cancer. Am J Clin Pathol. 2016;145(6):871–8. https://doi.org/10.1093/ajcp/aqw045

Mendes D, Alves C, Afonso N, Cardoso F, Passos-Coelho JL, Costa L, et al. The benefit of HER2-targeted therapies on overall survival of patients with metastatic HER2-positive breast cancer – a systematic review. Breast Cancer Res. 2015;17(140):1–14. http://dx.doi.org/10.1186/s13058-015-0648-2

Rinnerthaler G, Gampenrieder SP, Greil R. HER2 directed antibody-drug-conjugates beyond T-DM1 in breast cancer. Int. J. Mol. Sci. 2019;20,1115:1–17. https://doi.org/10.3390/ijms20051115

Zlobec I, Terracciano L, Jass JR, Lugli A. Value of staining intensity in the interpretation of immunohistochemistry for tumor markers in colorectal cancer. Virchows Arch. 2007;451:763–9. https://doi.org/10.1007/s00428-007-0466-8